相关实验视频

Updated: Jul 12, 2025

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

英克利西兰:新一代的降脂siRNA治疗药物

Yanzhen Zhang¹, Huaigang Chen^2,3, Lang Hong³

¹Department of Rheumatology, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital, Beijing, China.

Frontiers in pharmacology

|October 30, 2023

概括

新型siRNA药物Inclisiran有效降低LDL-C以预防动脉样硬化性心脏病 (AHD) 通过不频繁的剂量. 需要进一步研究其长期安全性,成本和相互作用.

科学领域:

心血管医学心血管医学
药理学药理学是指药理学的学科.
遗传学是一个遗传学.

背景情况:

动脉样性心脏病 (AHD) 是全球死亡的主要原因.
降低低密度脂蛋白胆固醇 (LDL-C) 对AHD预防和治疗至关重要.
需要新的治疗策略来改善脂质管理.

研究的目的:

审查Inclisiran的机制,疗效,安全性和应用.
将Inclisiran与现有的降脂疗法,特别是PCSK9抑制剂进行比较.
为Inclisiran确定当前的挑战和未来的研究方向.

主要方法:

对最近关于Inclisiran的研究进行文献综述.
对针对PCSK9基因表达的Inclisiran作用机制的分析.
对Inclisiran与其他降脂药物的比较评估.

主要成果:

英克利西兰是一种siRNA治疗药物,可显著降低LDL-C水平.
它提供了一个方便的剂量方案 (每年两到三次注射).
对于心血管风险较高的患者来说,Inclisiran 是有前途的.

结论:

英克利西兰是治疗高脂血症和预防AHD的一种有前途的药物.
长期的安全性,成本效益,可访问性和药物相互作用需要进一步调查.
英克利西兰 (Inclisiran) 提供了一种新的脂质管理方法,对患者的坚持治疗有潜在的益处.

关键词:

这包括伊朗.在PCSK9中心血管疾病的风险.降脂疗法降脂疗法 siRNA 是一个RNA.

更多相关视频

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

相关概念视频

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Small interfering RNAs (siRNA)

Small interfering RNAs (siRNA)

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...